Critical role of interleukin (IL)-17 in inflammatory and immune disorders : An updated review of the evidence focusing in controversies
Ruiz de Morales, José María G. (Universidad de León)
Puig, Lluís (Universitat Autònoma de Barcelona. Departament de Medicina)
Daudén, Esteban (Hospital Universitario de la Princesa (Madrid))
Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona)
Pablos, José Luis (Hospital Universitario 12 de Octubre (Madrid))
Martín, Antonio Oliveira (Hospital Universitario La Paz (Madrid))
Juanatey, Carlos González (Hospital Universitario Lucus Augusti (Lugo))
Adan Civera, Alfredo (Hospital Clínic i Provincial de Barcelona)
Montalban, Xavier (Hospital Universitari Vall d'Hebron)
Borruel, Natalia (Hospital Universitari Vall d'Hebron)
Ortí, Guillermo (Vall d'Hebron Institut d'Oncologia)
Holgado-Martín, Esther (Ruber Internacional)
Garcia-Vidal, Carolina (Hospital Clínic i Provincial de Barcelona)
Vizcaya-Morales, Cynthia (Novartis Pharma)
Martín-Vázquez, Víctor (Novartis Farmacéutica)
González-Gay, Miguel Ángel (Universidad de Cantabria)

Date:	2020
Abstract:	Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	IL17A ; Psoriasis ; Inflammation ; Citoquine ; Immunology ; Biological drugs
Published in:	Autoimmunity Reviews, Vol. 19 Núm. 1 (january 2020) , p. 102429, ISSN 1873-0183

DOI: 10.1016/j.autrev.2019.102429
PMID: 31734402

15 p, 1.4 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles